AKT1 and type 2 diabetes mellitus: SELENOP administration reduced insulin-stimulated phosphorylation of both the insulin receptor and the protein kinase B (Akt) that can impair insulin signaling in hepatocytes, while genetic knockdown of hepatic Selenop1 alleviated both glucose intolerance and IR in mice with type 2 diabetes [69].